Annovis Bio, Inc.
ANVS
$2.67
$0.208.10%
NYSE
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -16.49% | 3.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 30.55% | 18.55% | |||
| Operating Income | -30.55% | -18.55% | |||
| Income Before Tax | -35.41% | -16.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.41% | -16.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.41% | -16.76% | |||
| EBIT | -30.55% | -18.55% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -4.23% | -15.57% | |||
| Normalized Basic EPS | -4.21% | -15.59% | |||
| EPS Diluted | -3.92% | -15.63% | |||
| Normalized Diluted EPS | -4.21% | -15.59% | |||
| Average Basic Shares Outstanding | 29.94% | 1.02% | |||
| Average Diluted Shares Outstanding | 29.94% | 1.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||